Skip to main content
OpenTrials
Completed

NCT Number: NCT05419258

Feasibility and Evaluation Study of the UPLUG Hemodialysis Connection Device

The new Uplug° technology, interface between the end of the hemodialysis catheter and the dialysis circuit, makes it possible to limit direct access to the hemodialysis catheter during connections and disconnections.

Aim:

The investigators propose a feasibility study, in order to study the new Uplug° technology in real conditions of use.

Material and methods:

This study aim to include 15 hemodialysis patients in a center on a tunneled permanent central venous hemodialysis catheter. The Uplug° technology will be placed at the end of each patient's hemodialysis catheter for a period of one month.

Hypothesis tested:

The main endpoint is the proportion of hemodialysis sessions performed successfully with this technology, respecting the usual dialysis prescription.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The incidence and prevalence of chronic insufficiency have been growing for several years. Increasingly older patients are treated with chronic hemodialysis. The vascular access of choice remains the arteriovenous fistula and the proportion of hemodialysis patients on the permanent central venous hemodialysis catheter varies from 20 to 35% in dialysis centres. The new Uplug° technology, interface between the end of the hemodialysis catheter and the dialysis circuit, makes it possible to limit direct access to the hemodialysis catheter during connections and disconnections.

Aim:

The investigators propose a feasibility study, in order to study the new Uplug° technology in real conditions of use.

Material and methods:

This study aim to include 15 hemodialysis patients in a center on a tunneled permanent central venous hemodialysis catheter. The inclusion period is three months. The follow-up time for each participant is 6 weeks. Patients with a tunneled permanent central venous hemodialysis catheter and performing dialysis sessions with a flow rate ≥ 300 ml/min may be included. The Uplug° technology will be placed at the end of each patient's hemodialysis catheter for a period of one month.

Hypothesis tested:

The main endpoint is the proportion of hemodialysis sessions performed successfully with this technology, respecting the usual dialysis prescription.

The secondary objectives are the infectious risk, the defects of the experimental device and the hemodialysis catheter or their implementation, the satisfaction of the nursing staff and the patient, the reduction in the number of manipulations and the effective time of these manipulations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • with end-stage chronic renal failure treated by hemodialysis (2 or 3 sessions per week)
  • Wearer of a right or left jugular permanent tunneled central venous hemodialysis catheter whose end has been in the superior vena cava or the right atrium for at least 1 month
  • Hemodialysis catheter lock used = heparin or 4% citrate
  • Expected life expectancy > 6 months
  • Dialysis session preceding inclusion with an average blood flow of at least 300ml/min

Exclusion criteria

  • Patient with a mechanical heart valve
  • Patient with an arteriovenous fistula (AVF) that can be used within one month
  • Kidney transplant by living donor planned in the following month
  • Pregnant or breastfeeding woman
  • History of infection on the hemodialysis catheter in place dating from less than 6 months
  • Psychiatric or demented patient unable to obtain informed consent
  • Patient already included in another protocol

Treatment and study plan

UPLUG Hemodialysis Connection Device

Device

use of the device UPLUG during 1 month

Primary outcomes

  1. success in performing dialysis

    Time frame: one month

    Study the feasibility of performing dialysis with the UPlug Technology in patients with a permanent tunneled central venous hemodialysis catheter with the objective of a success rate ≥ 80%.

Secondary outcomes

  1. Number of participants with Adverse Events [Safety and Tolerability] of the experimental device UPLUG

    Time frame: one month

    adverse events reported from consent to end of study

  2. experimental device integrity

    Time frame: one month

    device deficiencies reported from consent to end of study

  3. nurses' satisfaction

    Time frame: one month

    satisfaction evaluated by questionnaire before and after the inclusions

  4. patient satisfaction

    Time frame: one month

    satisfaction evaluated by questionnaire before and after the use of experimental device

  5. clinical performance of device

    Time frame: one month

    performance measured by rate of successful sessions

Sponsors and collaborators

Lead sponsor

University Hospital, Caen

Other

Registry information

Acronym: UPLUG-SAFE

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jun 15, 2022
Registry last updated
Feb 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.